Found vs SkinnyRx (2026): prices, structure, verdict

On tirzepatide, Found is cheaper: $289 versus $299 a month all-in — a $10 monthly gap, $120 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, SkinnyRx↗ is cheaper: $199 versus $289 a month all-in — a $90 monthly gap, $1,080 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Found: the record, condensed

Found’s tirzepatide program bills $289 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Found is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes Found unusually easy to compare and unusually easy to leave.

To place the number: #6 of 17 verified programs, with the floor $74/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

Found’s semaglutide program bills $289 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #15 of 20 in the verified semaglutide index — $156/month above the floor (Oak Longevity, $133) — and sits $60 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $3,468.

Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗

SkinnyRx: the record, condensed

On tirzepatide, the number that matters at SkinnyRx is $299 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes SkinnyRx unusually easy to compare and unusually easy to leave.

To place the number: #7 of 17 verified programs, with the floor $84/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $150 a month. A year at this figure: $3,588 monthly-billed.

On semaglutide, the number that matters at SkinnyRx is $199 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at SkinnyRx is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $199 is the whole subscription, which makes SkinnyRx unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #11 of 20 in the verified semaglutide index — $66/month above the floor (Oak Longevity, $133) — and sits $150 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,388.

Operationally at SkinnyRx: shipping included; commitment none; cancellation no membership on compounded programs; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the SkinnyRx page · visit SkinnyRx ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: Found at $289, SkinnyRx at $299 — a $10 monthly spread that compounds to $120 over a maintenance year and $240 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $10 gap is exactly what it appears to be.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $199 (SkinnyRx) against $289 (Found). $90 a month sounds survivable; $1,080 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $90 gap is exactly what it appears to be.

A way to feel the $10 monthly gap: over a year it funds 0.4 extra months at Found’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $240, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: Found $289/mo month-to-month against SkinnyRx $299/mo month-to-month. The order holds: Found leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Found $867 monthly; SkinnyRx $897 monthly — best path favors Found by $30. 6 months: Found $1,734 monthly; SkinnyRx $1,794 monthly — best path favors Found by $60. 12 months: Found $3,468 monthly; SkinnyRx $3,588 monthly — best path favors Found by $120. 24 months: Found $6,936 monthly; SkinnyRx $7,176 monthly — best path favors Found by $240.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Found $867 vs SkinnyRx $597 — $270 to SkinnyRx. 6 mo: Found $1,734 vs SkinnyRx $1,194 — $540 to SkinnyRx. 12 mo: Found $3,468 vs SkinnyRx $2,388 — $1,080 to SkinnyRx. 24 mo: Found $6,936 vs SkinnyRx $4,776 — $2,160 to SkinnyRx.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Found publishes “most states”; SkinnyRx publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Found — none month-to-month; prepaid terms for lowest rate; membership recurs; prepaid terms are paid up front. SkinnyRx — none; no membership on compounded programs.

Insurance: only Found does coverage work — decisive if there is any chance your plan covers a brand GLP-1, because a covered prescription beats both cash paths on this page.

Evidence: Found third-party reported (captured 2026-08-05); SkinnyRx source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #6 and #7 of 17: between them lie 0 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #15 and #11 of 20: between them lie 3 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Found and SkinnyRx

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Found: membership recurs; prepaid terms are paid up front; SkinnyRx: no membership on compounded programs) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings